natgillin/translations-raw huggingface dataset:
Sodium chloride Potassium chloride Disodium phosphate dihydrate Potassium dihydrogen phosphate Water for injections 
Viala z antigenom: tiomersal natrijev klorid kalijev klorid natrijev hidrogenfosfat dihidrat kalijev dihidrogenfosfat voda za injekcije
Pharmacovigilance The MAH commits to submit the data from pregnancy 
Farmakovigilanca Imetnik dovoljenja za promet z zdravilom se obvezuje, da bo posredoval podatke iz svojega internega registra nosečnosti kot je zabeleženo v Načrtu za obvladovanje
Split influenza virus*, inactivated containing antigen equivalent to: A/California/7/2009 (H1N1)-like strain (NYMC X-179A).......................................3.8 micrograms** 
Po premešanju 1 odmerek (0,5 ml) vsebuje: inaktivirane delce virusa gripe, ki vsebujejo antigene*, ki ustrezajo: sevu A/California/7/2009 (X-179A) podobnemu sevu A/California/7/2009 (H1N1).........3,8 mikrogramov** * namnožen v jajcih ** izražen v mikrogramih hemaglutinina
Excipients: sodium chloride, potassium chloride, disodium phosphate dihydrate, potassium dihydrogen phosphate and water for injections. 
Pomožne snovi: natrijev klorid, kalijev klorid, natrijev hidrogenfosfat dihidrat, kalijev dihidrogen fosfat in voda za injekcije.
Excipients: thiomersal, sodium chloride, potassium chloride, disodium phosphate dihydrate, potassium dihydrogen phosphate and water for injections. 
Pomožne snovi: tiomersal, natrijev klorid, kalijev klorid, natrijev hidrogenfosfat dihidrat, kalijev dihidrogenfosfat in voda za injekcije.
Seroconversion rate** % [95% CI] 
Delež serokonverzije** % [95 % IZ]
Children from 6 months to less than 3 years of age: 
Otroci od 6 mesecev do 3 let starosti:
Suspension and emulsion for emulsion for injection. 
suspenzija in emulzija za emulzijo za injiciranje Antigen je brezbarvna, bistra do opalescentna suspenzija.
Children from 6 to 35 months of age: 
Otroci, stari od 6 do 35 mesecev:
Very common: feeling generally unwell, muscular pain, headache, shivering, fever. 
Zelo pogosti: splošno slabo počutje, bolečina mišic, glavobol, tresavica, zvišana telesna temperatura.
* Proportion of subjects achieving a post-vaccination titer ≥1:40 ** For subjects with a pre-vaccination titer <1:10, proportion of subjects with a post-vaccination titer ≥1:40 and for subjects with a pre-vaccination titer ≥1:10, proportion of subjects with a ≥four-fold increase from pre- to post-vaccination titer *** Geometric mean of individual ratios (post-/pre-vaccination titers) 
* Razmerje oseb, ki imajo po cepljenju titer ≥ 1 : 40 ** Za osebe, ki imajo pred cepljenjem titer < 1 : 10 ., razmerje oseb, ki imajo po cepljenju titer ≥ 1 : 40, in za osebe, ki imajo pred cepljenjem titer ≥ 1 : 10 , razmerje oseb z ≥ štirikratnim porastom titra po cepljenju glede na titer pred cepljenjem *** Geometrično povprečje posameznih razmerij (titri pred cepljenjem in po njem)
In an open-label clinical trial, two half-doses (0.25 ml) of HUMENZA have been administered at a 3week interval in 48 children from 6 to 11 months of age and in 48 children from 12 to 35 months of age. 
V odprtem kliničnem preskušanju so 48 otrokom, starim od 6 do 11 mesecev in 48 otrokom, starim od 12 do 35 mesecev, aplicirali dva polovična odmerka (0,25 ml) cepiva HUMENZA v 3-tedenskem intervalu.
Total enrolled subjects N= 49 
Skupno vključeni preiskovanci N = 99
STATEMENT OF ACTIVE SUBSTANCE(S) Split influenza virus*, inactivated, containing antigen equivalent to: A/California/7/2009 (H1N1)-like strain (NYMC X-179A)..............................................................30 µg** For 1 ml 
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN Po premešanju 1 odmerek (0,5 ml) vsebuje: inaktivirane delce virusa gripe, ki vsebujejo antigene*, ki ustrezajo: sevu A/California/7/2009 (X-179A) podobnemu sevu A/California/7/2009 (H1N1)....................................................................................................................3,8 mikrogramov** * namnožen v jajcih ** hemaglutinin
The seroprotection rate corresponds to the proportion of subjects achieving a post-vaccination titer 
Delež serozaščite odgovarja razmerju, ko so cepljene osebe dosegle titer po cepljenju ≥ 1 : 40.
Seroconversion factor*** [95% CI] * Proportion of subjects achieving a post-vaccination titer ≥1:40 ** For subjects with a pre-vaccination titer <1:10, proportion of subjects with a post-vaccination titer ≥1:40 and for subjects with a pre-vaccination titer ≥1:10, proportion of subjects with a ≥four-fold increase from pre- to post-vaccination titer *** Geometric mean of individual ratios (post-/pre-vaccination titers) 
Faktor serokonverzije*** [95 % IZ] * Razmerje oseb, ki so dosegli po cepljenju titer ≥ 1 : 40 ** Za osebe, ki imajo pred cepljenjem titer < 1 : 10, razmerje oseb, ki imajo po cepljenju titer ≥ 1 : 40 in za osebe, ki imajo pred cepljenjem titer ≥ 1 : 10 , razmerje oseb z ≥ štirikratnim porastom titra po cepljenju glede na titer pred cepljenjem *** Geometrično povprečje posameznih razmerij (titri pred cepljenjem in po njem)
At the injection site: pain, redness, swelling, bruising, hardness. 
Na mestu injiciranja: bolečina, pordelost, oteklina, modrica, otrdelost.
There are no data with HUMENZA using the subcutaneous route. 
Podatkov o subkutani uporabi cepiva HUMENZA ni.
Viral shedding was assessed by measuring viral replication in both nasal and throat swabs and results demonstrated that HUMENZA was able to consistently reduce the viral load in the upper respiratory tract. 
Rezultati so pokazali, da cepivo HUMENZA dosledno zmanjšuje količino virusov v zgornjih dihalih.
In the event of either being observed (including rubber particles from the stopper), the vaccine should be discarded. 
Če opazite eno ali drugo(vključno z delci gume iz zamaška),,
Very common: feeling generally unwell, muscular pain, shivering, fever. 
Zelo pogosti: splošno slabo počutje, bolečina mišic, tresavica, zvišana telesna temperatura.
Children from 3 years of age, adolescents and adults up to 60 years of age: One dose of 0.5 ml at an elected date. 
Otroci, starejši od 3 let, mladostniki in odrasli do 60 let starosti:
At the injection site: pain, redness, hardness, swelling. 
Na mestu injiciranja: bolečina, pordelost, oteklina, otrdelost.
HUMENZA consists of two vials: one vial containing the antigen (suspension) and one vial containing the adjuvant (emulsion), which are mixed prior to use. 
Cepivo HUMENZA je sestavljeno iz dveh vial: ena viala vsebuje antigen (suspenzijo), druga viala pa vsebuje adjuvans (emulzijo).
HUMENZA should be stored in a refrigerator (2°C-8°C) and should be used within 24 hours Medicines should not be disposed of via wastewater or household waste. 
Cepivo HUMENZA shranjujte v hladilniku (2 °C-8 °C) in uporabite v 24 urah.
No case of overdose have been reported. 
4.9 Preveliko odmerjanje Ni poročil o primerih prevelikega odmerjanja.
Common: fever, sore throat, injection site bruising. 
Pogosti: zvišana telesna temperatura, vneto grlo.
For the dose to be administered, see recommended posology in section 3 
Za odmerek, ki ga je treba aplicirati, glejte priporočila o odmerjanju v poglavju 4.2 »Kako se daje zdravilo HUMENZA«.
Marketing Authorization. 
- Navodilo shranite.
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Antigen for HUMENZA 
IME ZDRAVILA IN POT(I) UPORABE Antigen za zdravilo HUMENZA cepivo proti pandemski gripi (H1N1)
Adjuvant vial: 
10 vial
Common: injection site bruising, diarrhoea. 
Pogosti: modrica na mestu injiciranja, driska.
Injection site pain Injection site erythema Injection site swelling Injection site induration Injection site ecchymosis Fever (≥ 38°C) Headache 
2. odmerek bolečina/občutljivost na mestu injiciranja eritem na mestu injiciranja oteklina na mestu injiciranja induracija na mestu injiciranja ekhimoza na mestu injiciranja od 12 do 23 mesecev od 24 do 35 mesecev odmerek odmerek odmerek odmerek zvišana telesna temperatura glavobol navzea mialgija tresavica bruhanje neobičajno jokanje zaspanost izguba apetita razdražljivost
Children (12 to 35 months of age) 
Otroci (stari od 12 do 35 mesecev) N = 48
Total enrolled subjects N= 48 
N = 48
This study comprised a total of 665 patients. 
Ta študija obsega skupno 665 bolnikov.
Date of first authorisation: 25 February 2013 Date of latest renewal: 10 November 2017 
Datum prve odobritve: 25. februar 2013 Datum zadnjega podaljšanja: 10. novembra 2017
During pivotal trials the greatest improvement was observed within the first 4 weeks. 
V pivotalnih preskušanjih je bil največji napredek opažen v prvih 4 tednih.
The estimated volume of distribution (Vd/F) is approximately 3200 l. 
Ocenjeni volumen porazdelitve (Vd/F) je približno 3.200 l.
1 year study 
Enoletna študija
Elderly patients (≥65 years of age) 
Starejši bolniki (≥ 65 let)
How and when to take 
Kako in kdaj vzeti odmerek
A high level of alcohol consumption is associated with an increased risk of health and social problems. 
Visoka stopnja uživanja alkohola je povezana z večjim tveganjem za zdravstvene in socialne težave.
EU/1/12/815/001 7 tablets EU/1/12/815/002 14 tablets EU/1/12/815/003 28 tablets EU/1/12/815/004 42 tablets EU/1/12/815/005 98 tablets EU/1/12/815/006 49 tablets 
EU/1/12/815/001 7 tablet EU/1/12/815/002 14 tablet EU/1/12/815/003 28 tablet EU/1/12/815/004 42 tablet EU/1/12/815/005 98 tablet EU/1/12/815/006 49 tablet
Reduction of alcohol consumption is an intermediate goal on the way to abstinence. 
Zmanjšanje uživanja alkohola je vmesni cilj na poti do abstinence.
Together you will decide how to continue. 
Skupaj se bosta odločila glede nadaljevanja zdravljenja.
At randomisation, these patients consumed such a small amount of alcohol that there was little room for further improvement (floor effect). 
Pri randomizaciji so ti bolniki zaužili tako majhne količine alkohola, da je bilo malo prostora za nadaljnje izboljšave (učinek tal).
Alcohol dependence occurs when a person has a physical or psychological dependence on the consumption of alcohol. 
Odvisnost od alkohola se pojavi, ko ima oseba fizično ali psihološko odvisnost od uživanja alkohola.
This effect was considered to be an indirect effect related to toxicity to the dams. 
Ta učinek se je smatral za posredni učinek, povezan v povezavi s toksičnostjo za samice.
In this post hoc population, the treatment effect was larger than that in the total population. 
V tej (post hoc) populaciji je bil učinek zdravljenja večji kot v celotni populaciji.
This change is considered unlikely to be of clinical relevance. 
Ta sprememba najverjetneje ni klinično pomembna.
However, the frequency of these side effects cannot be estimated from the available data. 
Vendar pogostnost teh neželenih učinkov ni mogoče oceniti iz razpoložljivih podatkov.
The tablet is engraved with ‘S' on one side. 
V tableto je vtisnjena oznaka "S" na eni strani.
Frequencies are defined as: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), or not known (cannot be estimated from the available data). 
Pogostnosti so opredeljene kot: zelo pogosti (≥ 1/10), pogosti (od ≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000) ali neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
- You should take the tablet 1-2 hours before you start drinking alcohol. 
- Tableto morate vzeti 1-2 uri pred pitjem alkohola.
- Do not use this medicine if you notice defects in the tablets, such as chipped or broken tablets. 
- Ne uporabljajte tega zdravila, če opazite napake na tabletah, kot so okrušene ali zlomljene tablete.
An updated RMP shall be submitted annually until renewal. 
Posodobljen RMP je treba predložiti vsako leto do podaljšanja dovoljenja.
Therefore, the patients who maintained a high or very high DRL at randomisation were defined post hoc as the target population. 
Zato so bolniki, ki so ohranili visoko ali zelo visoko DRL pri randomizaciji, bili opredeljeni post hoc kot ciljna populacija.
In some cases, it may be difficult for you to distinguish side effects from the symptoms you may feel when you reduce your alcohol consumption. 
V nekaterih primerih je lahko težko razlikovati neželene učinke od simptomov, ki jih lahko občutite pri zmanjšanju uživanja alkohola.
These side effects may affect your skills when driving or doing anything that requires you to be alert, including operating machinery. 
Ti neželeni učinki lahko vplivajo na vaše spretnosti, ko vozite ali delate karkoli, kar zahteva vašo pozornost, vključno z upravljanjem strojev.
- Your doctor will follow up with you on a regular basis, for example, monthly after you start treatment with Selincro; the actual frequency will depend on your progress. 
- Zdravnik bo redno spremljal vaše zdravljenje, na primer mesečno po začetku zdravljenja z zdravilom Selincro; dejanska pogostnost bo odvisna od vašega napredka.
Libido decreased (including loss of libido) 
Zmanjšana spolna sla (vključno z izgubo libida)
Nalmefene does not exhibit any substantial pharmacokinetic differences between sexes, between young and elderly, or between ethnic groups. 
Nalmefen ne kaže pomembnih farmakokinetičnih razlik med spoloma, med mladimi in starejšimi ali med etničnimi skupinami.
Patients with severe hepatic impairment (Child-Pugh classification). 
Bolniki s hudo okvaro jeter (razvrstitev po Child-Pughu).
Responder analyses of the pooled data from the two studies are provided in Table 2. 
Odzivnostne analize zbranih podatkov iz dveh študij so podane v preglednici 2.
Caution is advised if treatment aimed at reduction of alcohol consumption is started in such patients. 
Potrebna je previdnost, če zdravljenje, usmerjeno v zmanjšanje uživanja alkohola, začnemo pri takšnih bolnikih.
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu . 
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu.
Clinical data for the use of Selincro under randomised controlled conditions are available for a period of 6 to 12 months. 
Klinični podatki o uporabi zdravila Selincro pod randomiziranimi kontroliranimi pogoji so na voljo za obdobje od 6 do 12 mesecev.
Thereafter, the patient should be asked to record his or her alcohol consumption for approximately two weeks. 
Zatem je bolnika ali bolnico treba pozvati, da beleži svoje uživanje alkohola približno dva tedna.
No unusual pattern of adverse reactions was observed in these settings, but experience is limited. 
Nenavaden vzorec neželenih učinkov v teh pogojih ni bil zaznan, vendar so izkušnje omejene.
- You can expect to be able to reduce your alcohol consumption within the first month after you start treatment with Selincro. 
- Pričakujete lahko, da boste zmožni zmanjšati uživanje alkohola v prvem mesecu po začetku zdravljenja z zdravilom Selincro.
Patients with severe renal impairment (eGFR <30 ml/min per 1.73 m 
Bolniki s hudo okvaro ledvic (eGFR < 30 ml/min na 1,73 m
The physician should continue to assess the patient's progress in reducing alcohol consumption, overall functioning, treatment adherence, and any potential side effects. 
Zdravnik mora še naprej ocenjevati bolnikov napredek pri zmanjševanju uživanja alkohola, celotno delovanje, vztrajanje pri zdravljenju in morebitne stranske učinke.
7 film-coated tablets 14 film-coated tablets 28 film-coated tablets 42 film-coated tablets 49 film-coated tablets 98 film-coated tablets 
7 filmsko obloženih tablet 14 filmsko obloženih tablet 28 filmsko obloženih tablet 42 filmsko obloženih tablet 49 filmsko obloženih tablet 98 filmsko obloženih tablet
For example, a bottle of wine (750 ml; 12% alcohol by volume) contains approximately 70 g alcohol and a bottle of beer (330 ml; 5% alcohol by volume) contains approximately 13 g alcohol. 
Na primer, steklenica vina (750 ml; 12 % volumski delež alkohola) vsebuje približno 70 g alkohola in steklenica piva (330 ml, 5 % volumski delež alkohola) vsebuje približno13 g alkohola.
Selincro can be taken with or without food (see section 5.2). 
Zdravilo Selincro se lahko jemlje s hrano ali brez nje (glejte poglavje 5.2).
Selincro should not be used in children or adolescents below the age of 18 years because Selincro has not been tested in this age group. 
Zdravilo Selincro se ne sme uporabljati pri otrocih ali mladostnikih, mlajših od 18 let, ker zdravilo Selincro pri tej starostni skupini ni bilo preizkušeno.
If you are going to have a surgical procedure, talk to your doctor at least 1 week before the procedure. 
Če boste imeli kirurški poseg, se posvetujte z zdravnikom vsaj teden dni pred posegom.
A significant reduction in the number of HDDs and TAC occurred in some patients in the period between the initial visit (screening) and randomisation due to non-pharmacological effects. 
Do pomembnega zmanjšanja števila HDDs in TAC je prišlo pri nekaterih bolnikih v obdobju od začetnega obiska (presejalni pregled) in randomizacije zaradi ne-farmakološkega učinka.
- You can take Selincro with or without food. 
- Zdravilo Selincro lahko jemljete s hrano ali brez nje.
Your use of Selincro may affect your doctor's choice of emergency treatment. 
Uporaba zdravila Selincro lahko vpliva na zdravnikovo izbiro nujnega zdravljenja.
The average protein-bound fraction of nalmefene in plasma is approximately 30%. 
Povprečen delež nalmefena v plazmi, ki je vezan na proteine, je približno 30 %.
While these events were generally shortlasting, they could represent alcoholic psychosis, alcohol withdrawal syndrome, or comorbid psychiatric disease. 
Čeprav so bili ti učinki v glavnem kratkotrajni, bi lahko predstavljali alkoholno psihozo, sindrom odtegnitve od alkohola ali komorbidno psihiatrično bolezen.
Caution is advised if Selincro is prescribed for more than 1 year. 
Potrebna je previdnost, če je zdravilo Selincro predpisano za več kot 1 leto.
After you stop treatment with Selincro, you may be less sensitive to the effects of medicines containing opioids for a few days. 
Ko prenehate z zdravljenjem z zdravilom Selincro, ste lahko nekaj dni manj občutljivi za učinke zdravil, ki vsebujejo opioide.
However, body size seems to affect the clearance of nalmefene to a minor degree (clearance increases with increasing body size), but this is considered unlikely to be of clinical relevance. 
Vendar pa telesna velikost vpliva na očistek nalmefena v manjšem obsegu (očistek se poveča pri večji telesni velikosti), vendar pa je malo verjetno, da bi to bilo klinično pomembno.
The maximum dose of Selincro is one tablet per day. 
Največji odmerek zdravila Selincro je ena tableta na dan.
If you take medicines containing opioids, the effects of these medicines will be reduced, or the medicines may not work at all if you take them together with Selincro. 
Če jemljete zdravila, ki vsebujejo opioide, se bodo učinki teh zdravil zmanjšali ali morda zdravila sploh ne bodo delovala, če jih boste jemali skupaj z zdravilom Selincro.
An HDD was defined as a day with a consumption ≥60 g of pure alcohol for men and ≥40 g for women. 
HDD je bil definiran kot dan z zaužitimi ≥ 60 g čistega alkohola za moške in ≥ 40 g za ženske.
Somnolence Tremor 
Zaspanost Tremor
Pharmacotherapeutic group: Other nervous system drugs, drugs used in alcohol dependence; ATC code: N07BB05 
Farmakoterapevtska skupina: Druga zdravila z delovanjem na živčevje, zdravila za zdravljenje zasvojenosti z alkoholom, oznaka ATC: N07BB05
It is not known if Selincro is safe to use during pregnancy and breast-feeding. 
Ni znano, ali je zdravilo Selincro varno za uporabo med nosečnostjo in dojenjem.
A high level of alcohol consumption is defined as drinking more than 60 g of pure alcohol per day for men and more than 40 g of pure alcohol per day for women. 
Visoka stopnja uživanja alkohola je opredeljena kot pitje več kot 60 g čistega alkohola na dan za moške in več kot 40 g čistega alkohola na dan za ženske.
Very common (may affect more than 1 in 10 people) - feeling sick - dizziness - inability to sleep - headache 
Zelo pogosti (lahko se pojavijo pri več kot 1 od 10 bolnikov) - slabost - omotica - nezmožnost spanja - glavobol
52% of these patients had a high or very high DRL at baseline; of these, 52% (representing 27% of the total population) continued to have a high or very high DRL at randomisation. 
52 % teh bolnikov je imelo visoko ali zelo visoko DRL v izhodišču; od teh je 52 % (kar predstavlja 27 % celotne populacije) še naprej imelo visoko ali zelo visoko DRL pri randomizaciji.
Your doctor will provide you with counselling to help you keep to your treatment and thereby reduce your alcohol consumption. 
Zdravnik vam bo s svetovanjem pomagal ostati na zdravljenju in s tem zmanjšati vaše uživanje alkohola.
At baseline, the patients had, on average, 23 HDDs per month (11% of patients had fewer than 14 HDDs per month) and consumed 106 g/day. 
V izhodišču so imeli bolniki povprečno 23 HDDs na mesec (11 % bolnikov je imelo manj kot 14 HDDs na mesec) in uživanje 106 g/dan.
The majority of the patients had low (55% had a score of 0-13) or intermediate (36% had a score of 14-21) alcohol dependence according to the Alcohol Dependence Scale. 
Večina bolnikov je imela nizko (55 % je imelo 0-13 točk) ali srednjo (36 % je imelo 14-21 točk) odvisnost od alkohola glede na lestvico odvisnosti od alkohola (Alcohol Dependence Scale).
This is unlikely to present a problem with occasional use, but if long-term concurrent treatment with a potent UGT2B7 inhibitor is initiated, a potential for an increase in nalmefene exposure cannot be excluded (see section 4.4). 
Malo verjetno je, da bi to predstavljalo problem pri občasni uporabi, vendar pa pri uvedbi dolgoročnega sočasnega zdravljenja z močnim zaviralcem UGT2B7, možnosti povečane izpostavljenosti nalmefenu ne moremo izključiti (glejte poglavje 4.4).
Intake of a single dose of 450 mg nalmefene has been reported without changes in blood pressure, heart rate, respiration rate, or body temperature. 
Po poročanju vnos enkratnega odmerka 450 mg nalmefena ni povzročil sprememb v krvnem tlaku, srčnem utripu, frekvenci dihanja ali telesni temperaturi.
Overall, the studies included 1,941 patients, 1,144 of whom were treated with Selincro 18 mg as-needed. 
Skupno sta študiji vključevali 1.941 bolnikov, od katerih se jih je 1.144 zdravilo z odmerkom 18 mg zdravila Selincro z režimom odmerjanja po potrebi.
If you feel detached from yourself, see or hear things that are not there, and this continues to recur for more than a few days, stop taking Selincro and talk to your doctor. 
Če se počutite odmaknjeni od sebe, vidite ali slišite stvari, ki jih ni in to traja več kot nekaj dni, prenehajte z jemanjem zdravila Selincro in se posvetujte s svojim zdravnikom.
Nalmefene Odds Ratio (95% CI) p-value 
Nalmefen Razmerje obetov (95 % IZ) p-vrednost
Each film-coated tablet contains 60.68 mg lactose. 
Ena filmsko obložena tableta vsebuje 60,68 mg laktoze.
Psychiatric effects were reported in clinical studies (see section 4.8). 
Pri kliničnih študijah so poročali o psihiatričnih učinkih (glejte poglavje 4.8).
Selincro is to be taken as-needed: On each day the patient perceives a risk of drinking alcohol, one tablet should be taken, preferably 1-2 hours prior to the anticipated time of drinking. 
Zdravilo Selincro je treba jemati po potrebi: vsak dan, ko bolnik zazna, da obstaja tveganje pitja alkohola, mora vzeti eno tableto, po možnosti 1-2 uri pred predvidenim časom pitja.
However, the effect of nalmefene and alcohol in combination did not exceed the sum of the effects of each substance when taken alone. 
Vendar pa učinek kombinacije nalmefena in alkohola ni presegel vsote učinkov, ki nastanejo pri jemanju posameznih snovi.
The prescriber should advise patients that it is important to inform their health care professional of last Selincro intake if opioid use becomes necessary. 
Zdravnik mora svetovati bolnikom, da je pomembno obvestiti svojega zdravstvenega delavca o zadnjem jemanju zdravila Selincro, če uporaba opioidov postane potrebna.
Inform your doctor about any other diseases you may have, for example, depression, seizure, liver or kidney disease. 
Obvestite svojega zdravnika o vseh drugih boleznih, ki jih imate, na primer depresija, epileptični napad, okvara jeter ali ledvic.